Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I-NAPA
NCT05027633Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2021
- Primary completion
- Mar 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in squamous cell carcinoma of the nasal cavity (SNSCC), squamous cell carcinoma of the paranasal sinuses (SNSCC), sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2021; status: recruiting.
02
Drugs
03
Conditions
squamous cell carcinoma of the nasal cavity (SNSCC)squamous cell carcinoma of the paranasal sinuses (SNSCC)
Beyond the preview
Go deeper on NCT05027633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05027633.